GMAB vs INSM

Genmab A/S and Insmed Incorporated, both Healthcare

Genmab A/S is the larger company at $33B against $26B. GMAB keeps 29 cents of operating profit from each dollar of sales against -37 for INSM, and INSM grew sales faster over the last year, +240% against +19%. Over the past year GMAB returned +75% against -38% for INSM.

Genmab A/S and Insmed Incorporated compared on valuation multiples, growth, margins and return
FigureGMABINSM
Last close$50.98$120
Market cap$33B$26B
Trailing P/E33.2n/a
Revenue growth+19%+240%
Operating margin29%minus 37%
Net margin26%minus 40%
Free cash flow yield3.5%n/a
Net cash$3.6B net debt$592M
Insiders, 12 monthsn/asold $162M net
1-year return+75%-38%
5-year return+9.6%+270%

Figures from SEC filings and end-of-day closes. Highlighting marks the higher number in each row, nothing more.

Genmab A/S

Revenue of $2.1B in the quarter to Dec 31, 2025, net income $432M.

Insmed Incorporated

Revenue of $524M in the quarter to Sep 30, 2026, net income null. Its largest reported line is United States, 60% of the disclosed total.

Open these two in the interactive comparison to add more names, change the period or see the correlation.